Advertisement
Clinical Roundup

Wistar researchers identify potential target for gastric cancers associated with Epstein-Barr Virus

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus. In a paper published in the journal mBio, Wistar’s Tempera lab investigates the epigenetic characteristics of gastric cancer associated with the Epstein-Barr Virus. In evaluating EBVaGC’s epigenetics—the series of biological signals associated with the genome that determines whether a given gene is expressed—the Tempera lab highlights a target that could advance as a future treatment for this type of cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

Drugs & Targets

FDA approves Vyloy+chemo for gastric or GEJ junction adenocarcinoma with CLDN18.2-positive tumors

FDA has approved Vyloy (zolbetuximab-clzb), a claudin 18.2-directed cytolytic antibody, with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are CLDN18.2 positive, as determined by an FDA-approved test.
Advertisement
Advertisement